RESEARCH ARTICLE
SA JOURNAL OF DIABETES & VASCULAR DISEASE
110
VOLUME 7 NUMBER 3 • SEPTEMBER 2010
and was influenced by demographic and clinical factors such as
age, gender, systolic blood pressure and body mass index. These
observations also raise major clinical and public health concerns,
including an inevitable increase in the prevalence of cardiovascular
diseases due to the increasing frequency of hypertension and other
cardiovascular risk factors in the population.
The cost of the management of cardiovascular disease
is enormous, therefore there is a serious economic burden
imposed, especially on developing countries. As urbanisation and
westernisation increase, the clustering of cardiovascular risk factors
is likely to be more common due to the expected increase in the
prevalence of high blood pressure. The potential economic impact
will be huge. Therefore lifestyle modification measures need to
be reinforced, as they have the potential to reduce cardiovascular
disease arising from the epidemic of obesity and the metabolic
syndrome.
References
1.
World Health Report 2002. Reducing risks, promoting healthy life. Geneva,
Switzerland: World Health Organization, 2002. Available at: http: /
/ whr 2002. Accessed on May 2, 2005.
2.
Akinkugbe OO. The Nigerian hypertension programme.
J Human Hypertens
1996;
10
(Suppl 1): S43–S46.
3.
Cooper R, Rotimi C, Ataman S,
et al
. The prevalence of hypertension in seven
populations of West African origin.
Am J Publ Hlth
1997;
87
: 160–168.
4.
Kadiri S, Walker O, Salako BL, Akinkugbe O. Blood pressure, hypertension and
correlates in urbanized workers in Ibadan, Nigeria: a revisit.
J Hum Hypertens
1999;
13
: 23–27.
5.
Nilsson S. Research contributions of Eskil Kylin.
Sven Med Tidskr
2001;
5
: 15–28.
6.
Avogaro P, Crepald G, Enzi G,
et al
. Association of hyperlipidaemia, diabetes
mellitus and obesity.
Acta Diabetol Lat
1967;
4
: 36–41.
7.
Reaven G. Banting lecture 1988: Role of insulin resistance in human disease.
Diabetes
1988;
37
: 1595–1600.
8.
Isezuo SA, Badung SL, Omotoso AB. Comparative analyses of lipid profiles
among patients with type 2 diabetes mellitus, hypertension and concurrent type
2 diabetes and hypertension. A view of metabolic syndrome.
J Nat Med Ass
2003;
95
: 328–334.
9.
Obasohan AO, Ajuyah CO. How common is heart failure due to hypertension
alone in hospitalized Nigerians?
J Hum Hypertens
1996;
10
: 810–804.
10. Cornier MA, Dabelea D, Hernandez TL,
et al
. The metabolic syndrome.
Endocr
Rev
2008;
29
: 777–822.
11. Jeppesen J, Hansen TW, Ibsen H, Torp-Pedersen C, Madsbad S. Insulin resistance,
the metabolic syndrome, and the risk of incident cardiovascular disease: a
population-based study.
J Am Coll Cardiol
2007;
49
: 2112–2119.
12. Lakka HM, Laaksonen DE, Lakka TA,
et al
. The metabolic syndrome and total
and cardiovascular disease mortality in middle-aged men.
J Am Med Assoc
2002;
288
: 2709–2716.
13. Wilson PW, D’Agostino RB, Parise H, Sullivan L, Meigs JB. Metabolic syndrome
as a precursor of cardiovascular disease and type 2 diabetes mellitus.
Circulation
2005;
112
: 3066–3072.
14. Isomaa B, Almgren P, Tuomi T,
et al
. Cardiovascular morbidity and mortality
associated with the metabolic syndrome.
Diabetes Care
2001;
24
: 683–689.
15. McNeil AM, Rosamond WD, Girman CJ,
et al.
The metabolic syndrome and
11-year risk of incident cardiovascular disease in the atherosclerosis risk in
communities study.
Diabetes Care
2005;
28
: 385–390.
16. Gami AS, Witt BJ, Howard DE,
et al
. Metabolic syndrome and risk of incident
cardiovascular events and death: a systematic review.
J Am Coll Cardiol
2007;
49
: 403–414.
17. Expert Panel on Detection, Evaluation and Treatment of High Blood Cholesterol
in Adults. Executive summary of the third report of the NCEP expert panel on
detection and treatment of high blood cholesterol in adults. (Adult Treatment
Panel III).
J Am Med Assoc
2001;
285
: 2486–2497.
18. Okpechi IG, Pascoe MD, Swanepoel CR,
et al
. Microalbuminuria and the metabolic
syndrome in non diabetic Black Africans.
Diab Vasc Dis Res
2007;
4
(4): 365–367.
19. Barrios V, Escobar C, Calderon A,
et al
. Prevalence of the metabolic syndrome in
patients with hypertension treated in general practice in Spain: An assessment of
blood pressure and low density lipoprotein cholesterol control and accuracy of
diagnosis.
J Cardiomet Syndr
2007;
2
(1): 9–15.
20. Prussian KH, Barksdale-Brown DJ, Dieckmann J. Racial and Ethnic differences in
the presentation of metabolic syndrome.
J Nurse Pract
2007;
3
(4): 229–239.
21. Kesteloot H, Oviasu VO, Obasohan AO,
et al
. Serum lipid and apolipoprotein
levels in a Nigerian population sample.
Atherosclerosis
1989;
78
(1): 33–38.
22. Wilson PW, D’Agostino RB, Levy D,
et al
. Prediction of coronary heart disease
using risk factor categories.
Circulation
1998;
97
: 1837–1847.
23. Scuteri A, Najar SS, Muller DC,
et al
. Metabolic syndrome amplifies the age-
associated increases in vascular thickness and stiffness.
J Am Coll Cardiol
2004;
43
: 1388–1395.
24. Marroquin DC, Laksmen D, Lakka T,
et al
. The metabolic syndrome and total
cardiovascular disease mortality in middle aged men.
J Am Med Assoc
2002;
288
: 2709–2716.
25. Hu G, Qiao Q, Tuomilehto J,
et al
. For the DECODE study group. Prevalence of
metabolic syndrome and its relation to all cause morbidity and cardiovascular
mortality in non-diabetic European men and women.
Arch Int Med
2004;
164
:
1066–1076.
26. Isezuo SA. Systemic hypertension in Blacks: An overview of current concepts of
pathogenesis and management.
Nig Postgrad Med J
2003;
10
(3): 144–153.
27. DeFronzo RA, Ferrannini E. Insulin resistance: A multifaceted syndrome for
NIDDM, obesity, hypertension, dyslipidaemia and atherosclerotic cardiovascular
disease.
Diabetes Care
1991;
14
: 173–194.
28. Cornier MA, Dabelea D, Hernandez TL,
et al
. The metabolic syndrome.
Endocr
Rev
2008;
29
: 7Jeppesen J, Hansen TW, Ibsen H, Torp-Pedersen C, Madsbad S.
Insulin resistance, the metabolic syndrome, and the risk of incident cardiovascular
disease: a population-based study.
J Am Coll Cardiol
2007;
49
: 2112–2119.
29. Tonstad S, Sandvik E, Laren PG, Thelle D. Gender differences in the prevalences
and determinants of the metabolic syndrome in screened subjects at risk for
coronary heart disease.
Metab Syndr Relat Disord
2007;
5
(2): 174–182.
30. Njeleka MA, Mpembeni R, Muhihi A,
et al
. Gender related differences in the
prevalence of cardiovascular disease risk factors and their correlates in Urban
Tanzania.
BMC Cardiovasc Disord
2009;
17
(9): 30.
31. Ayodele OE, Alebiosu CO, Salako BL, Awoden OG Adigun AD. Target organ
damage and associated clinical conditions among Nigerians with treated
hypertension.
Cardiovasc J South Afr
2005;
16
(2): 89–93.
32. Alebiosu CO, Odusan BO. Metabolic syndrome in subjects with metabolic
syndrome.
J Natl Med Asso
2004;
96
: 817–821.
33. Yusuf S, Reddy S, Dompao S,
et al
. Global burden of cardiovascular disease: Part
I: General considerations, the epidemiologic transition, risk factor and impact of
urbanization.
Circulation
2001;
104
: 2746–2753.
